Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One-Week radiation after breast cancer surgery could be just as good, with better looks

NCT ID NCT05417516

Disease control Sponsor: Ontario Clinical Oncology Group (OCOG) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 4 times

Summary

This study compares two types of radiation therapy for women with early-stage breast cancer who have had a lumpectomy. One group receives radiation to the whole breast, the other only to the area where the cancer was removed. Both treatments are given once a day for about one week. The goal is to see if the shorter, partial treatment works as well at preventing cancer from coming back and causes fewer cosmetic changes to the breast. The study plans to enroll 910 women across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
radiation therapy
What this could lead to
If successful, this could offer a shorter, more convenient radiation option after breast cancer surgery that preserves breast appearance.
What could go wrong
This is a large Phase 3 trial, but results are not yet available. Partial breast radiation may not control cancer as well as whole breast radiation in the long term.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 910 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2023

Expected to finish

Nov 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 120 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For inclusion in this study, patients must fulfill all of the following criteria: 1. Female with a new histological diagnosis of invasive carcinoma of the breast with no evidence of metastatic disease (see AJCC TNM Cancer Staging, Appendix II). 2. Treated by BCS with microscopically clear resection margins \>= 1mm for invasive and non-invasive disease or no residual disease on re-excision. 3. Negative axillary node involvement as determined by either sentinel lymph node biopsy or axillary node dissection or clinical assessment with a negative axillary ultrasound and/or biopsy, for women with unifocal tumours \<= 2cm, histologic grade 1 or 2, ER or PR+ and HER2-ve that are being planned for endocrine therapy Exclusion Criteria: Patients who satisfy any of the following exclusion criteria are NOT eligible for this study: 1. Age less than 50 years. 2. Known to be BRCA 1 and/or BRCA 2 positive. 3. Tumour size \>3cm in greatest diameter on pathological examination. 4. Evidence of extensive intraductal component (EIC) (defined as an invasive tumour with a ductal carcinoma in situ (DCIS) component comprising at least 25% and extending beyond the invasive component to surrounding normal breast tissue) with the following exception: smaller tumours with EIC where the combined size (of the invasive and DCIS components) are \<= 3cm remain eligible 5. Evidence of a DCIS component \> 3cm 6. Lobular carcinoma only. 7. More than one primary tumour in different quadrants of the same breast (patients with multifocal breast cancer are eligible). 8. Synchronous or previous contralateral breast cancer (patients with contralateral DCIS or LCIS are eligible). 9. History of non-breast malignancy within the last 5 years other than treated non-melanoma skin cancer or treated in-situ carcinoma. 10. Known pregnancy or currently lactating. 11. Inability to localize tumour bed on CT planning (no evidence of surgical clips or seroma). 12. Inability to plan the patient for the experimental technique.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast neoplasm female are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast neoplasm invasive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast neoplasm female Cosmetic outcome Radiotherapy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    31 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Algoma District Cancer Program

    RECRUITING

    Sault Ste. Marie, Ontario, Canada

  • Arthur J. E. Child Comprehensive Cancer Centre-Clinical Research Unit

    RECRUITING

    Calgary, Alberta, Canada

  • BC Cancer - Vancouver Island Centre

    RECRUITING

    Victoria, British Columbia, Canada

  • BCCA-Vancouver Island Cancer Centre

    NOT_YET_RECRUITING

    Victoria, British Columbia, Canada

  • CHUM - Centre Hospitalier de L'Université de Montréal

    RECRUITING

    Montreal, Quebec, H2L 4M1, Canada

  • CHUQ-Pavillon Hotel-Dieu de Quebec

    RECRUITING

    Québec, Quebec, Canada

  • CHUS-Hopital Fleurimont

    RECRUITING

    Sherbrooke, Quebec, J1H5N4, Canada

  • CSSS Champlain - Charles LeMoyne

    RECRUITING

    Greenfield Park, Quebec, Canada

  • Centre Intégré Universitaire de Santé et de Services Sociaux de la Mauricie-Centre-du-Québec (CIUSSS MCQ)

    RECRUITING

    Trois-Rivières, Quebec, G8Z 3R9, Canada

  • GenesisCare Bedford Park

    RECRUITING

    Bedford Park, South Australia, 5042, Australia

  • GenesisCare Bundaberg

    RECRUITING

    Bundaberg, Queensland, 4670, Australia

  • GenesisCare Darlinghurst

    RECRUITING

    Darlinghurst, New South Wales, 2010, Australia

  • GenesisCare Fiona Stanley Hospital

    RECRUITING

    Murdoch, Western Austrailia, 6150, Australia

  • GenesisCare Hervey Bay

    RECRUITING

    Urraween, Queensland, 4655, Australia

  • GenesisCare Hollywood

    RECRUITING

    Nedlands, Western Australia, 6009, Australia

  • GenesisCare Hurstville

    RECRUITING

    Hurstville, New South Wales, 2220, Australia

  • GenesisCare Mater Hospital

    RECRUITING

    North Sydney, New South Wales, 2060, Australia

  • GenesisCare Southport

    RECRUITING

    Southport, Queensland, 4215, Australia

  • GenesisCare St Andrew's

    RECRUITING

    Adelaide, South Australia, 5000, Australia

  • GenesisCare Tugun

    RECRUITING

    Tugun, Queensland, 4224, Australia

  • GenesisCare Wembley

    RECRUITING

    Wembley, Washington, 6014, Australia

  • Juravinski Cancer Centre

    RECRUITING

    Hamilton, Ontario, Canada

  • London Regional Cancer Centre

    RECRUITING

    London, Ontario, Canada

  • McGill University Health Centre

    RECRUITING

    Montreal, Quebec, Canada

  • Princess Margaret Hospital

    RECRUITING

    Toronto, Ontario, Canada

  • QEII HSC - Nova Scotia Cancer Centre

    RECRUITING

    Halifax, Nova Scotia, Canada

  • Royal Victoria Regional Health Centre

    RECRUITING

    Barrie, Ontario, Canada

  • Saskatoon Cancer Centre

    RECRUITING

    Saskatoon, Saskatchewan, S7N 4H4, Canada

  • Stronach (Southlake) Regional Health Centre

    RECRUITING

    Newmarket, Ontario, Canada

  • Toronto-Sunnybrook Health Sciences Centre - Odette Cancer Centre

    RECRUITING

    Toronto, Ontario, Canada

  • Windsor Regional Cancer Centre

    RECRUITING

    Windsor, Ontario, N8W2X3, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.